William Blair Issues Optimistic Forecast for argenx Earnings

argenx SE (NASDAQ:ARGX - Free Report) - Investment analysts at William Blair boosted their FY2026 earnings per share (EPS) estimates for argenx in a research note issued on Friday, February 28th. William Blair analyst M. Minter now expects that the company will earn $26.61 per share for the year, up from their previous forecast of $26.08. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share. William Blair also issued estimates for argenx's FY2027 earnings at $28.62 EPS and FY2028 earnings at $40.92 EPS.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

Several other research analysts have also weighed in on ARGX. Oppenheimer upped their target price on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Evercore ISI increased their price objective on argenx from $675.00 to $706.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Wedbush reiterated an "outperform" rating and issued a $655.00 target price on shares of argenx in a research note on Tuesday, December 3rd. Wells Fargo & Company increased their price target on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Finally, Wolfe Research raised shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price objective for the company in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $662.83.

Remove Ads

argenx Stock Performance

NASDAQ:ARGX traded down $18.75 during trading hours on Monday, hitting $617.74. 81,976 shares of the company's stock traded hands, compared to its average volume of 280,914. The stock's fifty day moving average price is $642.47 and its two-hundred day moving average price is $592.89. The firm has a market cap of $37.53 billion, a P/E ratio of -700.01 and a beta of 0.58. argenx has a twelve month low of $349.86 and a twelve month high of $678.21.

Hedge Funds Weigh In On argenx

Several institutional investors have recently modified their holdings of ARGX. GeoWealth Management LLC raised its holdings in argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the period. Whipplewood Advisors LLC bought a new stake in shares of argenx during the fourth quarter worth $37,000. Global Retirement Partners LLC raised its holdings in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares during the period. FIL Ltd bought a new stake in argenx in the 4th quarter valued at $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in argenx during the 4th quarter worth about $38,000. Institutional investors own 60.32% of the company's stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.